StockData
Neuphoria Therapeutics Inc. logo

Neuphoria Therapeutics Inc. (NEUP) stock

NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026Score 5/30
$2.48−0.07 (-2.75%)

Close on Nov 16, 2026Market cap $74.56KP/E –Yield –

Neuphoria Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2026 it was $1.17M, down 92.5% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2026Jun 30, 2026$1.17M-92.5%
FY2025Jun 30, 2025$15.65M–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2025CQ1 2025Mar 31, 2025$15.00M–
Q2 FY2025CQ4 2024Dec 31, 2024$662.72K–

More Neuphoria Therapeutics figures

See a number that looks wrong?